Revenue and net profit both grew over 8% year-over-year, driven by a 47% surge in innovative drug sales and strong medical device growth. R&D investment reached 29% of revenue, and a cash dividend of ¥5.50 per 10 shares was proposed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.